1 Like
Om du leser historikken min så ser jeg større potensiale i både bgbio og trvx samt pcib enn nano 
3 Likes
Fikk lastet med en trade på 49 i dag og tok 25% av bordet i slutt auksjonen, for å sikre litt profitt og ha mulighet til å kjøpe en sell on news osv, resterende står 
God helg og lykke til 
Sitter på mine aksjer også.
Har fått lastet litt mer sist uke så snittprisen min er 29,05.
Det er ikke meningen og skryte av dette.
NANO og Targovax aksjene er kraftig i minus.
Hadde tenkt og handle litt mer idag men syntes den hadde gått litt mye med 4% igår og 4% idag.
Da kan dere banne på at den vil stige ytteligere.
Spennende selskap med mange muligheter til å nå mål.
Samarbeidet med Merck er jo heller ikke noe minus.
Edit:
Min største frykt på kort og mellomlang sikt er om Trond Mohn skulle begynne og sikkre gevinst.
Men han virker jo som en som sitter langsiktig.
1 Like
Er ikke så alt for lenge siden Mohn solgte bank aksjene sine, for å gi en slant på et par hundre millioner til småpikene sine så han er jeg ikke videre bekymret for.
Rein spekulasjon, men at Mohn som var en av de første og største investorene kommer til å selge før enten oppkjøp, kommersialisering eller kroken på døren -det tviler jeg sterkt på.
1 Like
Der er handlet 200 stk. aktier på 49 i dag - at det lige skulle være dine er super flot og mega sejt gjort. Du tjente 125,-
Stort tillykke herfra 
49,xx her, for å spesifisere ytterligere for deg. Så kan du dra fram igjen kalkulatoren din.
Utover det kan du jobbe litt med tonen din her inne og forsøke å holde en sivilisert profil.
4 Likes
That makes two of us. Jeg har litt penger nokså jevnt spredt utover de tre med litt tyngre vekting på Targo og BGBIO. Targo mest pga gunstig inngang i tilegg til lovende takter, BGBIO da jeg har stor tro på dem.
1 Like
BerGenBio ASA US CLINICAL TRIAL UPDATE
BERGEN, Norway, June 2 , 2018 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
multiple cancer indications, announces that the Norwegian National Ethics
Committee (NEM) have granted approval for clinical trials related to Non-Small
Cell Lung Cancer.
In November 2017, BerGenBio informed that the Company was in voluntary
discussions with the Regional Ethics Committee (REK) in Bergen and the Norwegian
Board of Health about gaining retrospective approval for the study.In March 2018, BerGenBio informed that NEM gave a notice of non-acceptance.
BerGenBio is pleased to inform that a acceptance now is in place.
Hence, as of today all necessary domestic and foreign approvals have now been
acquired.-End-
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors as a potential
cornerstone of combination cancer therapy. The Company is a world leader in
understanding the essential role of AXL kinase in mediating cancer spread,
immune evasion and drug resistance in multiple aggressive solid and
haematological cancers.BerGenBioŽs lead product, bemcentinib (BGB324), is a selective, potent and
orally bio-available small molecule AXL inhibitor in four Company sponsored
Phase II clinical trials in major cancer indications, with read-outs anticipated
during 2018. It is the only selective AXL inhibitor in clinical development.The Company sponsored clinical trials are:
- Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven
non-small cell lung cancer (NSCLC)- Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and
- Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC).
- Bemcentinib as a single agent and combination therapy in acute myeloid
leukaemia (AML) / myeloid dysplastic syndrome (MDS)The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the
lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth,
NJ, USA), through a subsidiary.In addition, a number of investigator-sponsored trials are underway, including a
trial to investigate bemcentinib with either MEKINIST® (trametinib) plus
TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial
combining bemcentinib with docetaxel in advanced NSCLC.
BerGenBio is simultaneously developing a companion diagnostic test to identify
patient subpopulations most likely to benefit from treatment with bemcentinib.
This will facilitate more efficient registration trials and support a precision
medicine based commercialization strategy.The Company is also developing a diversified pre-clinical pipeline of drug
candidates, including BGB149, an anti-AXL monoclonal antibody.For further information, please visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of
OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a
registered trademark of Novartis International AG and MEKINIST® is a registered
trademark of GSK plc.Contacts
Richard Godfrey
CEO
BerGenBio ASA
+47-917-86-304Rune Skeie
CFO
BerGenBio ASA
rune.skeie@bergenbio.com
+47-917-86-513Media Relations in Norway
Jan Petter Stiff
Crux Advisors
stiff@crux.no
+47-995-Ekstern link: http://www.newsweb.no/index.jsp?messageId=452839
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180602.OBI.20180602S4
[/details]
2 Likes
Som mange vet, så har BerGenBio i likhet med Nordic Nanovector hatt utfordringer med REK.
Uten noe videre om og men, uten noe støy rundt prosessen, så har altså selskapet løst denne utfordringen.
Jeg blir mer og mer imponert over Richard Godfrey, CEO i BerGenBio.
Se og lær, andre-biotek-selskaper, se og lær.
3 Likes
Hadde nok vært litt mer støy om Bergen hadde hatt samme kursreisen som nordic. Edit: og infopolicy!
Uansett, det virker å være standarden at REK fort bruker 6 mnd+ for å smelle gjennom en godkjenning. Det er noe norske myndigheter bør ta innover seg. Det går utover pasienter, bransjen og eierne.
1 Like
BerGenBio har nå større MCAP enn Nano, kursen er mindre volatil og går stort sett i en retning.
Ingen støy, bare suksess.
Nordic sin infopolicy bør jo stilles ut på museum, det der må jo ha vært et forsøk på moderne kunst. Performance-art!
1 Like
Bergen er nok der NANO en gang var. Så får man håpe de makter å bygge videre på det med både informasjon og resultater.
Det er sant, uten resultater så blir alt bare store ord.
Vi krysser fingre og tær i spenning!
3 Likes
Se der ja, første godmelding allerede tidlig lørdag. Den meldingen var 100% bonus for min del.
3 Likes
BerGenBio provides interim update on Phase II clinical programme with selective oral AXL inhibitor bemcentinib
Chicago, IL, USA, June 3 2018- BerGenBio ASA (OSE:BGBIO) announces that interim
data from its Phase II clinical development programme with bemcentinib, a
selective AXL inhibitor, was presented at a reception hosted yesterday by the
company in Chicago, IL, USA. The reception, which coincides with the annual
American Society of Clinical Oncology (ASCO) meeting, provided stakeholders,
including clinicians, investors, analysts and media, with interim data from the
ongoing clinical trials of bemcentinib alone and in combination with standard of
care drugs in multiple cancer indications. Presentations were made by key
opinion leaders, clinical trial principle investigators and members of the
BerGenBio team.
All materials presented at the reception are available on the BerGenBio website
in the Investors / Presentations section. A conference call to discuss the
presentations and updates will be held on Monday 4thJune at 8:30 AM CEST
(details below).Key Findings
Note that all Phase II trials are ongoing and results presented are preliminary
and subject to change as the trials progress to completion. Updated data will be
presented throughout 2018.· Bemcentinib plus KEYTRUDA® (pembrolizumab) shows early promise in advanced
lung cancer (NSCLC) patients who failed previous treatment (study BGBC008):
· Tumour shrinkage was reported in 8 of 15 evaluable patients to date,
including three Partial Responses (PR) and one mixed response,
· Response assessment according to biomarker expression analysis
available thus far:
· 6 of 7 PD-L1 negative patients reported clinical benefit, including 2
PRs and 2 patients with evidence of tumour shrinkage.
· 5 of 6 patients thus far tested for AXL expression with BerGenBio’s
proprietary immunohistochemistry assay, were AXL positive.
· 4 of 5 AXL positive patients reported clinical benefit including 1 PR
and 2 patients with evidence of tumour shrinkage.
· All 4 AXL positive patients reporting clinical benefit were found to be
PD-L1 negative.· An acceptable safety profile of the combination was reported with only aminority of patients experiencing fully reversible adverse events.
· Analysis of metastatic triple-negative breast cancer (TNBC) patients who had
failed previous treatment and who were enrolled to receive bemcentinib plus
KEYTRUDA (study BGBC007) showed low prevalence of AXL and PD-L1:
· 14 of 18 patients tested for AXL expression were AXL negative and reported
no benefit.
· 12 of 15 patients tested for PD-L1 expression were PD-L1 negative; 6 were
evaluable for efficacy with 1 reporting tumour shrinkage.· Superior response rates to bemcentinib monotherapy in relapsed/refractory
(R/R) acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) could be
predicted by soluble AXL (plasma sAXL) levels as determined by liquid biopsy
(study BGBC003):
· 20 R/R AML and MDS patients who were evaluable for response were analysed
for pre-treatment plasma sAXL
· 12 of 13 patients reporting sAXL levels below pre-defined thresholds at
pre-treatment experienced clinical benefit, including 3 Complete Remissions, 3
Partial Remissions.
· 6 of 7 patients with sAXL above the threshold experienced a best
response of progressive disease.· Bemcentinib in combination with established first-line therapies (KEYTRUDA
or MEKINIST (dabrafenib) plus TAFINLAR (trametinib) in unresectable melanoma was
well tolerated and showed encouraging tumour responses:
· 15 of 19 evaluable patients showed evidence of tumour shrinkage and to
date there were 2 CRs, 8 PRs and a further 6 patients with a best overall
response of stable disease.
· Blood-based biomarker candidates were identified.· Bemcentinib in combination with targeted therapy TARCEVA® (erlotinib) or
docetaxel chemotherapy (trials BGBC004 and BGBIL005, respectively) continue to
show promising activity in heavily pre-treated patients:
· Part C of the BGBC004 trial of bemcentinib in combination with EGFR
targeted therapy introduces bemcentinib in a first-line setting in patients who
have achieved their optimum benefit from TARCEVA monotherapy. 5 of 6 evaluable
patients showed evidence of tumour shrinkage including 1 PR and 1 mixed
response. In parts A and B, patients who achieved an objective response continue
on treatment.
· 3 of 7 (43%) evaluable patients in a trial combining bemcentinib and
docetaxel (BGBIL005) achieved durable PRs in a disease setting where the
response rate to docetaxel monotherapy is expected to be 10-20%.· BerGenBio continues to develop a Bemcentinib companion diagnostic
· A standardised AXL immunohistochemistry (IHC) assay, has reported strong
correlation with tumour response to bemcentinib treatment.
· Blood-based biomarkers continue to report correlation with tumour response
to bemcentinib treatment with particularly encouraging results in R/R AML and
MDS.Richard Godfrey, BerGenBio CEO, commented: “We are excited to present these very
encouraging interim results from our broad Phase II clinical development
programme in a variety of tumour types with a significant unmet medical need.
These results continue to support our view that bemcentinib could become a
cornerstone of future cancer therapy. This data provides further evidence of
bemcentinib’s activity in patients whose cancer progression is mediated by AXL.
In addition, we are making good progress with our studies to identify predictive
biomarkers that we anticipate may be developed as companion diagnostics for
personalized therapy. We look forward to advancing these studies to completion
and defining the future development strategy of bemcentinib with the greatest
value for patients.”Abstracts to be presented at ASCO
Monday 4 June, 8:00 AM - 11:30 AM Central Daylight Time
· Interim data from BGBC008 - Poster Board: #292, Abstract 3078
· Interim data from BGBC003 - Poster Board: #80, Abstract 7020
· To be discussed at the Poster Discussion Session. 11:30 AM - 12:45 PM· Biomarker study - Poster Board: #385, Abstract 2559
Monday 4 June, 1:15 PM - 4:45 PM CDT
· Interim data from BGBIL006 - Poster Board: #375, Abstract 9548
The posters presented at ASCO will be made available www.bergenbio.comin the
Investors / Presentations section following the sessions.Conference call
A conference call to discuss the presentations from the reception and those to
be presented at ASCO will take place on Monday 4 June 2018 at 08:30 AM CEST.
Details of the call are available in the Investors section of the BerGenBio
website (www.bergenbio.com). A recording of the call will be available shortly
after the event at the same place. A presentation will be available
at www.bergenbio.com in the section: Investors/Reports and presentations from
8:00 am CEST the same day.-End-
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors as a potential
cornerstone of combination cancer therapy. The Company is a world leader in
understanding the essential role of AXL kinase in mediating cancer spread,
immune evasion and drug resistance in multiple aggressive solid and
haematological cancers.BerGenBio’s lead product, bemcentinib (BGB324), is a selective, potent and
orally bio-available small molecule AXL inhibitor in four Company sponsored
Phase II clinical trials in major cancer indications, with read-outs anticipated
during 2018. It is the only selective AXL inhibitor in clinical development.The Company sponsored clinical trials are:
· Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven non
-small cell lung cancer (NSCLC)
· Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and
· Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC).
· Bemcentinib as a single agent and combination therapy in acute myeloid
leukaemia (AML) / myeloid dysplastic syndrome (MDS)The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the
lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth,
NJ, USA), through a subsidiary.In addition, a number of investigator-sponsored trials are underway, including a
trial to investigate bemcentinib with either MEKINIST® (trametinib) plus
TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial
combining bemcentinib with docetaxel in advanced NSCLC.BerGenBio is simultaneously developing a companion diagnostic test to identify
patient subpopulations most likely to benefit from treatment with bemcentinib.
This will facilitate more efficient registration trials and support a precision
medicine based commercialization strategy.The Company is also developing a diversified pre-clinical pipeline of drug
candidates, including BGB149, an anti-AXL monoclonal antibody.For further information, please visit: www.bergenbio.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary
of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of
OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a
registered trademark of Novartis International AG and MEKINIST® is a registered
trademark of GSK plc.Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513Media Relations in Norway
Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891International Media Relations
David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson
bergenbio@citigatedewerogerson.com
+44 207 638 9571This information is subject to the disclosure requirements pursuant to se
Ekstern link: http://www.newsweb.no/index.jsp?messageId=452840
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180603.OBI.20180603S2
2 Likes
Hva har det seg at selskapet ikke prioriterer å presentere resultatene sine på konferanser? Ser ut som de slipper data litt her og der.
Ellers så skjønner jeg ikke hva stigningen beror på. Som kombinasjonsbehandling syns jeg dette virket noe under pari.
De presenterer 4 abstract på Asco i morgen. Men de skal også delta på veldig mange andre konfersaner gjennom året, ASH, SABCS, World Lung osv. Så jo, de skal presentere det på konferanser.
2 Likes
Skjønner. Ordlyden indikerte at de skulle slippes mer sporadisk.
Tanker om resultatene?